McKesson Co. (NYSE:MCK) Declares Quarterly Dividend of $0.41

McKesson Co. (NYSE:MCK) announced a quarterly dividend on Wednesday, October 23rd, RTT News reports. Investors of record on Monday, December 2nd will be given a dividend of 0.41 per share on Thursday, January 2nd. This represents a $1.64 annualized dividend and a dividend yield of 1.12%.

Shares of NYSE MCK traded down $0.86 during mid-day trading on Wednesday, hitting $146.06. 1,382,178 shares of the stock traded hands, compared to its average volume of 1,972,389. The stock has a fifty day moving average price of $140.37 and a 200-day moving average price of $134.13. The company has a market cap of $27.25 billion, a price-to-earnings ratio of 10.76, a PEG ratio of 1.47 and a beta of 1.14. McKesson has a 52 week low of $106.11 and a 52 week high of $153.30. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.58 and a current ratio of 1.01.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.04 by $0.27. The business had revenue of $55.73 billion during the quarter, compared to analysts’ expectations of $54.03 billion. McKesson had a return on equity of 30.73% and a net margin of 0.27%. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.90 earnings per share. As a group, sell-side analysts predict that McKesson will post 14.39 EPS for the current fiscal year.

A number of research analysts have issued reports on MCK shares. Wolfe Research cut McKesson from an “outperform” rating to a “peer perform” rating in a research note on Monday, August 5th. Cleveland Research reiterated a “hold” rating on shares of McKesson in a research note on Thursday, September 5th. JPMorgan Chase & Co. started coverage on McKesson in a research note on Monday, July 22nd. They set an “overweight” rating and a $164.00 price objective for the company. Bank of America set a $160.00 price objective on McKesson and gave the company a “buy” rating in a research note on Wednesday, July 31st. Finally, ValuEngine cut McKesson from a “sell” rating to a “strong sell” rating in a research note on Friday, August 30th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $147.20.

In other news, SVP Sundeep G. Reddy sold 422 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $143.79, for a total value of $60,679.38. Following the completion of the transaction, the senior vice president now owns 1,268 shares in the company, valued at $182,325.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Lori A. Schechter sold 1,275 shares of the business’s stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $150.00, for a total value of $191,250.00. Following the completion of the transaction, the executive vice president now owns 1,275 shares of the company’s stock, valued at approximately $191,250. The disclosure for this sale can be found here. Insiders sold 11,493 shares of company stock valued at $1,612,988 in the last 90 days. Company insiders own 0.88% of the company’s stock.

McKesson Company Profile

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

Featured Story: How Does the Quiet Period Work?

Dividend History for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit